Researchers identify new cell targets for preventing growth of breast and other tumors
...e proteins encoded by the candidate genes. They found that seven of the genes encoded membrane or secreted proteins. Four of these namely FAP, SFRP2, jak3
and SMPD3 had not just increased gene expression, but also increased protein expression in breast tumor vessels, and thus could be good targets for t...
St. Jude researchers find key step in programmed cell death
...e to keeping cells alive. For example, they demonstrated earlier that most cytokines controlling hematopoietic cells require an enzyme called Jak2, or jak3
in lymphocytes, at the receptors where cytokines attached to the cell.
In screening for components that are regulated by the Jak enzymes, the St. J...
Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
...vanced Phase 2 clinical studies for RA
and ITP this year, and also a Phase 2 clinical study in systemic lupus
erythematosus. In addition, Rigel's oral jak3
inhibitor, R348, is currently
in a Phase 1 study for the potential treatment of psoriasis and RA.
"Dan comes to Rigel with solid clinical research l...
New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer
...samples later identified two more mutations in the jak3
Thomas Mercher, a postdoctoral fellow ... a mouse model. "It was important to show that the jak3
mutation, when introduced in mice, would lead to a...leukemia-like illness. It did, confirming that the jak3
mutations play a central role in leukemia," said G...
Jak3 in Medical Technology
Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
young, healthy males using a double blind, placebo controlled, single dose
and multiple rising doses of R348. Results are expected in mid-2008.
in RA and Other Immune Disorders
RA affects approximately 1% of the population worldwide --
approximately 2.1 million Americans -- and is a debilita...
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
XL019 is a potent JAK2 inhibitor (IC50 = 2 nM) with excellent
selectivity versus the other members of the JAK kinase family (JAK1 IC50 =
130 nM, jak3
IC50 = 250 nM, TYK2 IC50 = 340 nM). It is active against both
wild type and mutationally activated forms of JAK2, and in preclinical
studies showed go...
Pharmacopeia Announces Third Quarter 2007 Financial Results
coupled with resources expended on the company's jak3
program. The expense
for the jak3
program has been primarily classified as collabora...Prior to 2007, resources expended on the
program were classified as proprietary research an...
Jak3 in Biological News
New strategy rapidly identifies cancer targets
...amples later identified two more mutations in the jak3
Thomas Mercher, a postdoctoral fellow i...a mouse model. "It was important to show that the jak3
mutation, when introduced in mice, would lead to...eukemia-like illness. It did, confirming that the jak3
mutations play a central role in leukemia," said...
Jak3 in Biological Technology